Physician profile
Eric S Cheung
NPI 1225015381
$19,613.71
in general payments reported to CMS, 2019-2025
54 companies · $2,185 in 2025
The $2,185 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,526 · 2020: $2,951 · 2021: $3,436 · 2022: $3,003 · 2023: $1,480 · 2024: $2,034 · 2025: $2,185.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,698.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,698.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $3,548.98 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $2,776.26 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $1,838.71 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $1,756.61 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Janssen Pharmaceuticals, INC | $1,407.97 | 2019-2024 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $1,107.10 | 2021-2025 | |
| Pfizer INC. | $799.52 | 2019-2025 | |
| Glaxosmithkline, LLC. | $745.17 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amarin Pharma, INC. | $436.86 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $435.21 | 2019-2025 | Ofev, Gilotrif, Jardiance |
| Merck Sharp & Dohme LLC | $382.84 | 2019-2021 | |
| Paratek Pharmaceuticals, INC. | $381.13 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $262.42 | 2023-2025 | Rexulti |
| Amgen INC. | $234.47 | 2019-2025 | Repatha, Repatha |
| Mylan Specialty L.P. | $233.42 | 2019-2024 | Yupelri |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Cheung listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.